The Research and Innovation Center of the Maccabi Healthcare Services has become the first laboratory in the world to use artificial intelligence to detect cancer in the gastrointestinal tract.
Follow Israel Hayom on Facebook and Twitter
Ibex Medical Analytics, a pioneer in artificial intelligence-based cancer diagnostics, announced this week the deployment of its AI-powered Galen Gastric at the leading health care provider's pathology institute.
According to the company, gastric cancer is among the most common malignant diseases in both men and women worldwide, with over a million new cases each year.
Pathologists play a crucial role in the detection and diagnosis of cancer – with their assessments being vital for reaching correct treatment decisions by oncologists and improving patient survival rates – however, a rise in cancer prevalence and advances in personalized medicine have resulted in growing diagnostic complexity that significantly increases the pathologists' workloads.
As labs transition towards digital solutions, pathologists can implement AI-enhanced workflows to improve the quality and efficiency of cancer diagnosis, resulting in better patient care.
Galen Gastric, which has recently been granted Breakthrough Device Designation by the United States Food and Drug Administration, can help pathologists improve the quality of cancer diagnosis, implement real-time quality control, reduce turnaround time and boost productivity.
The solution is an addition to Ibex Medical Analytics' Galen Prostate and Galen Breast that have already been deployed at Maccabi Healthcare Services, as well as other labs worldwide, where they are used in everyday clinical practice.
"We are excited to add Galen Gastric to what is the most comprehensive AI deployment in pathology, supporting us in providing quality diagnosis to our patients," Director of the Pathology Institute at Maccabi Healthcare Services Judith Sandbank said.
"The clinical benefits from using Ibex's AI solutions have been the key driver in Maccabi's decision to fully adopt digital pathology, and we are impressed by how fast AI technology has become an indispensable part of our diagnostic pathway. We look forward to benefiting from its new insights in everyday practice," she said.
Subscribe to Israel Hayom's daily newsletter and never miss our top stories
